Search research articles
Contact Us
Filters
Showing results (101-110 of 133) with videos related to
Page
of 14
Sort By:
American Journal of Obstetrics and Gynecology
|
February 26, 2022
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study
Phuong L Mai, Austin Miller, Amanda Black, et al.
JNCI Cancer Spectrum
|
April 28, 2020
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)
Phuong L Mai, Austin Miller, Mitchell H Gail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Gynecologic Oncology
|
August 25, 2023
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
Sandro Pignata, Michael Bookman, Jalid Sehouli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Charles N Landen, Luciana Molinero, Habib Hamidi, et al.
Gynecologic Oncology
|
May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study
Aaron M Praiss, Austin Miller, Judith Smith, et al.
Lancet (London, England)
|
February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
David M Gershenson, Austin Miller, William E Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2021
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N Moore, Michael Bookman, Jalid Sehouli, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 133) with videos related to
Sort By:
Page
of 14
American Journal of Obstetrics and Gynecology
|
February 26, 2022
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study
Phuong L Mai, Austin Miller, Amanda Black, et al.
JNCI Cancer Spectrum
|
April 28, 2020
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)
Phuong L Mai, Austin Miller, Mitchell H Gail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Gynecologic Oncology
|
August 25, 2023
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
Sandro Pignata, Michael Bookman, Jalid Sehouli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Charles N Landen, Luciana Molinero, Habib Hamidi, et al.
Gynecologic Oncology
|
May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study
Aaron M Praiss, Austin Miller, Judith Smith, et al.
Lancet (London, England)
|
February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
David M Gershenson, Austin Miller, William E Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2021
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N Moore, Michael Bookman, Jalid Sehouli, et al.
Page
of 14